Abstract
The aim of this work was to investigate major unresolved issues in cardiac stem cell therapy, including the optimal types and doses, the optimal delivery methods, and the biosafety and efficacy. In a canine acute myocardial ischemia model, we studied differences in bone marrow mesenchymal stem cell (BM-MSCs) distribution when delivered by transendocardial (TE) or intracoronary (IC) route. 10 Adult dogs (6 TE, 4 IC) received DAPI-labeled allogenic BM-MSCs (100×l06 cells) 7 days after occlusion/reperfusion of the left anterior descending (LAD) and were sacrificed 14 days later.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
